Sinefungin as treatment for American Leishmania in sensitive BALB/c and resistant C57BL/6 mice.
Using inbred BALB/c and C57BL/6 mice as animal models for American cutaneous leishmaniasis, we evaluated the inhibitory effect of sinefungin on foot-pad infection produced by 5 different Leishmania isolates. When treatment was initiated a few days, or even 2 weeks, after infection, an obvious leishmanicidal effect was detected on mice infected with Leishmania mexicana or L. braziliensis isolates, which lasted at least 50 weeks for all isolates studied. The optimal dose schedule was 4 mg/kg body weight/day, injected ip for 10 consecutive days; lower doses produced only a short leishmanistatic effect. The optimal dose found was 50-fold lower than the LD50. In vitro studies using Leishmania-infected murine peritoneal macrophages showed sinefungin as a powerful inhibitory drug, mean ED50 for the several Leishmania isolates studied being 50 ng/ml. No correlation was found between in vitro sensitivity of culture promastigotes and in vivo sensitivity to sinefungin of an American Leishmania isolate.[1]References
- Sinefungin as treatment for American Leishmania in sensitive BALB/c and resistant C57BL/6 mice. Avila, J.L., Rojas, T., Monzón, H., Convit, J. Am. J. Trop. Med. Hyg. (1990) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
